Few weeks before the UN General Assembly High Level Meeting on the fight against Tuberculosis, the EATG issues an open letter.

The FDA recently granted Fast Track designation to Assembly Biosciences, Inc’s novel treatment for patients with chronic hepatitis B virus (HBV) infection. The drug, ABI-H0731, is the manufacturer’s lead oral HBV core inhibitor, according to a press release.

Call for Membership (2018 – 2020) to the Developing Country NGO Delegation to the Board of The Global Fund to Fight AIDS, Tuberculosis and Malaria

This app provides mobile access to WHO PrEP Implementation Tool (WHO Implementation Tool for Pre-Exposure Prophylaxis of HIV Infection) and was developed to be a “digital pocket reference” available for clinicians and pharmacists. WHO has developed a series of modules to support the implementation of PrEP ...

Together we can prevent 2 million deaths by 2022

Ministers of health and senior policy-makers from 10 countries in eastern Europe and central Asia reaffirmed their political commitment to scale up national HIV responses during a ministerial policy dialogue on HIV, which was held on the eve of the International AIDS Conference in Amsterdam, ...

These guidelines aim to provide evidence-based recommendations on the care and treatment of persons diagnosed with chronic HCV infection. They update the care and treatment section of the WHO Guidelines for the screening, care and treatment of persons with hepatitis C infection issued in April 2016. The ...

Scientists announced important new developments in HIV treatment research at the 22nd International AIDS Conference (AIDS 2018) today.

Sir Elton John and the Duke of Sussex announce new global coalition focused on expanding diagnosis and treatment of HIV in men.

Gilead announces new data on the impact of Truvada® (emtricitabine and tenofovir disoproxil fumarate) for pre-exposure prophylaxis (PrEP) on the number of HIV diagnoses in the United States.

Merck announces week 96 data from pivotal Phase 3 drive-forward study of its investigational HIV therapy doravirine.

Safety concern over dolutegravir use in early pregnancy highlights limited contraception choices for many women living with HIV

More than 15,000 people gathered in Amsterdam today for the opening of the 22nd International AIDS Conference (AIDS 2018), where leaders focused on the major new investments, science-based policies and the political will needed to put the HIV response back on track.

[gview file="http://chasevirus.org/wp-content/uploads/2018/07/aids2018_pre-departure_guide_delegates.pdf"]

"People, politics and power lie at the heart of the AIDS epidemic. How these intersect will continue to be critically important in achieving the agreed global targets and universal health coverage".

Russian-speaking participants of AIDS2018 will be happy to know that key sessions will be provided with simultaneous translation into Russian. These sessions are: Opening, Rapporteur & Closing, all plenary sessions (8:45-10:30 daily) and all special sessions (13:00-14:00 daily). Other sessions in the list are collected ...

Scientists from UNSW Sydney and the UK have discovered that the human immunodeficiency virus (HIV) hijacks a small molecule from the host cell to protect itself from being destroyed by the host's immune system.

If you are going to the 22nd International AIDS Conference, this information may be useful. At the conference, a Harm Reduction Networking Zone (HRNZ) is located in the Global Village and is accessible to the general public (delegates and non-delegates). The HRNZ is the key area ...